Dicle yurdatap koç

Dr. Dicle yurdatap koç

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Oncology in Clinical Practice
Verified
Journal Article
Open access
PDF file
TATayyip İlker Aydın
Tayyip İlker Aydın
GÖGökhan Öztürk
Gökhan Öztürk
MHMuhammet Bekir Hacıoğlu
Muhammet Bekir Hacıoğlu
ETEbru Taştekin
Ebru Taştekin
DTDicle Tamer Türk
Dicle Tamer Türk
EDEce Demirdelen
Ece Demirdelen
Extra-gastrointestinal stromal tumors (EGISTs) primarily originate outside the gastrointestinal tract and are not associated with the walls of the stomach or intestines. They typically arise from the omentum, mesentery, peritoneum, retroperitoneum, and genitourinary regions. However, EGISTs originating from the prostate are exceedingly rare. Herein, a case is presented of an EGIST arising from prostatic tissue. The patient underwent radical prostatectomy. Histopathological examination revealed spindle-shaped tumor cells. Immunohistochemical analysis demonstrated positive expression of CD117, DOG-1, and CD34, leading to the diagnosis of a gastrointestinal stromal tumor (GIST). Radiologic staging showed no evidence of residual disease or metastasis; however, due to the high-risk nature of the tumor, adjuvant imatinib therapy was initiated. No recurrence or metastasis was observed during a one-year follow-up period, and the patient continues to be monitored regularly. This article also provides a comprehensive review of the clinical characteristics, histopathology, and treatment of EGIST cases reported in the literature. Keywords: gastrointestinal stromal tumor imatinib extra-gastrointestinal stromal tumor in the prostate

Verified
Journal Article
Open access
PDF file
İBİsmail Bayrakçı
İsmail Bayrakçı
DDDidem Divriklioglu
Didem Divriklioglu
GKGizem bakır kahveci
Gizem bakır kahveci
TATayyip İlker Aydın
Tayyip İlker Aydın
DKDicle yurdatap koç
Dicle yurdatap koç
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
Background/Objectives: Kaposi sarcoma (KS) is an HHV-8-associated angioproliferative malignancy with heterogeneous clinical presentation. Early lesions may be overlooked or misattributed to benign conditions, potentially causing diagnostic delay. We evaluated whether diagnostic delay was associated with survival outcomes in a real-world KS cohort. Methods: We retrospectively analyzed 87 consecutive patients with histologically confirmed KS diagnosed between 2007 and 2025. Diagnostic delay was defined as the interval between first patient-reported lesion/symptom recognition documented in medical records and histological diagnosis. An exploratory, maximally selected log-rank method was used to identify the delay cut-off that best separated overall survival (OS). OS and progression-free survival (PFS) were analyzed using Kaplan–Meier estimates, log-rank tests, and Cox regression models. Results: The exploratory optimal cut-off for diagnostic delay was 6.5 months, defining early (≤6.5 months; n = 46) and late (>6.5 months; n = 41) diagnosis groups. Median OS was 202.2 months (95% CI 62.3–342.1) in the early group and 92.9 months (95% CI 61.8–124.0) in the late group (log-rank p < 0.001). Late diagnosis was associated with a higher risk of death (HR 3.6, 95% CI 1.6–8.1; p = 0.001). This association was attenuated after multivariable adjustment and was no longer statistically significant (adjusted HR, 1.711, 95% CI 0.696–4.207; p = 0.242). Patients with late diagnosis were older (median 74 vs. 67 years, p = 0.004), had greater comorbidity burden (39.0% vs. 13.0%; p = 0.005), and more frequently had lymphedema (19.5% vs. 4.3%; p = 0.041). Conclusions: In this single-center KS cohort, longer diagnostic delay was associated with poorer post-diagnosis overall survival in unadjusted analyses, while this association was attenuated after multivariable adjustment. The exploratory 6.5-month threshold identified a subgroup with less favorable survival; however, this data-driven cut-off should be considered hypothesis-generating. These findings support efforts to improve early recognition, biopsy, and referral in KS, particularly in older and more comorbid patients.

Verified
Journal Article
Open access
PDF file
ŞIşuheda ataş ipek
şuheda ataş ipek
SYSendag Yaslikaya
Sendag Yaslikaya
IKIsmail Oguz Kara
Ismail Oguz Kara
TKTOLGA KÖŞECİ
TOLGA KÖŞECİ
EBErtugrul Bayram
Ertugrul Bayram
MBMahmut Buyuksimsek
Mahmut Buyuksimsek
Background: Sorafenib remains an important treatment option for patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). This study evaluated real-world outcomes and prognostic factors in patients treated with sorafenib. Materials and Methods: This retrospective multicenter study included 176 patients with RAI-R DTC treated with sorafenib between 2000 and 2024 across sixteen centers. Clinical, pathological and treatment-related variables, including metastatic sites, radiotherapy, dose reduction, inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte ratio [PLR]) and pretreatment thyroglobulin (Tg), were analyzed. Progression-free survival (PFS) was evaluated using Kaplan–Meier analysis. Prognostic factors were assessed using univariate and multivariate Cox regression analyses. Results: The median follow-up duration was 24 months and the median PFS was 21 months (95% CI: 15.5–26.5). Partial response was observed in 82 patients (46.6%), stable disease in 55 (31.3%) and progressive disease in 35 (19.9%). Patients who underwent dose reduction had longer PFS than those without dose reduction (42 vs. 19 months, p = 0.030), and absence of dose reduction remained independently associated with progression risk. Patients who received radiotherapy had shorter PFS than those who did not receive radiotherapy (16 vs. 37 months, p = 0.002), and radiotherapy-related variables remained independent predictors of progression. Patients with PLR values >138.2 had shorter PFS than those with PLR values ≤ 138.2 (19 vs. 34 months, p = 0.047), although this association was not maintained in Cox regression analysis. Similarly, associations between NLR and Tg values and PFS did not reach statistical significance (p = 0.112 and p = 0.072, respectively). Hand–foot syndrome was the most common toxicity, occurring in 59 patients (33.5%), while Grade 3 hand–foot syndrome was observed in 7 patients (4.0%). Conclusions: Sorafenib provided meaningful disease control with a median PFS of 21 months in this real-world cohort. Dose reduction was associated with longer PFS, whereas radiotherapy requirement appeared to reflect a higher-risk subgroup. Toxicities were generally manageable.

4 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDidem Divriklioglu
Didem Divriklioglu
İBİsmail Bayrakçı
İsmail Bayrakçı
GKGizem bakır kahveci
Gizem bakır kahveci
IGivo gokmen
ivo gokmen
DKDicle yurdatap koç
Dicle yurdatap koç
TTTopaloğlu Topaloğlu
Topaloğlu Topaloğlu
Background/Objectives: Clinical outcomes with immune checkpoint inhibitors (ICIs), such as nivolumab, vary among patients with metastatic non-small cell lung cancer (NSCLC). The Lung Immune Prognostic Index (LIPI) may help stratify prognosis. This study evaluated the prognostic significance of LIPI in patients receiving second- or third-line nivolumab and developed a nomogram for individualized survival estimation. Methods: This single-center retrospective study included 142 patients with metastatic NSCLC who received second- or third-line nivolumab between February 2022 and December 2024, after progression on platinum-based chemotherapy. LIPI was calculated from baseline values obtained within 14 days before nivolumab initiation, based on a derived neutrophil-to-lymphocyte ratio (dNLR) > 3 and lactate dehydrogenase (LDH) > 225 U/L (institutional upper limit of normal), classifying patients as good-, intermediate-, or poor-risk (0, 1, or 2 factors, respectively). Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan–Meier method; independent prognostic factors were assessed by multivariable Cox regression, and a prognostic nomogram combining ECOG performance status, serum albumin, and LIPI was developed and internally validated. Results: By LIPI, 34.5%, 45.1%, and 20.4% of patients were at good, intermediate, and poor risk, respectively. Objective response and disease control rates were 29.6% and 55.6%. Median OS and PFS were 19.3/8.0/3.1 and 8.6/3.1/2.5 months across good, intermediate, and poor LIPI groups (log-rank p < 0.001). In multivariable analysis, ECOG 2 (hazard ratio [HR], 4.94), albumin per 1 g/dL (HR 0.27), and poor versus good LIPI (HR 3.74) were independently associated with OS. A nomogram combining these three factors showed acceptable discrimination (optimism-corrected Harrell C-statistic 0.742). Conclusions: LIPI was independently associated with prognosis in this cohort. Combining LIPI with ECOG and albumin may aid individualized risk assessment, pending external validation.

9 June 2026 in Medicina
Verified
Journal Article
Open access
PDF file
AAAkgül Akgül
Akgül Akgül
SCSüleyman Can
Süleyman Can
IGivo gokmen
ivo gokmen
GKGizem bakır kahveci
Gizem bakır kahveci
IBİsmail Bayrakçı
İsmail Bayrakçı
BEBülent Erdoğan
Bülent Erdoğan
Background and Objectives: Systemic inflammation, nutritional impairment, and immune dysregulation are important determinants of outcomes in advanced malignancies. The C-reactive protein–albumin–lymphocyte (CALLY) index is a composite biomarker that reflects these biological domains, but its prognostic relevance in de novo metastatic gastric adenocarcinoma has not been well defined. Materials and Methods: This multicenter retrospective cohort study included 234 patients with de novo metastatic gastric adenocarcinoma treated between January 2015 and December 2025. Baseline CALLY was calculated before systemic treatment. A cohort-specific CALLY threshold of 1.21 was obtained using conventional ROC analysis, with all-cause mortality status at last follow-up as the binary outcome. Survival was evaluated using Kaplan–Meier analysis and Cox proportional hazards regression. To avoid guarantee-time bias, treatment exposure variables that became known only after treatment initiation, including the number of chemotherapy cycles delivered, were excluded from the baseline Cox models. Diagnosis period was included in the multivariable model to account for treatment-era heterogeneity. Results: Overall, 133 patients (56.8%) were classified as low-CALLY and 101 (43.2%) as high-CALLY. Median OS was significantly longer in the high-CALLY group than in the low-CALLY group (13.9 vs. 8.6 months; log-rank p < 0.001). Low CALLY was associated with inferior OS in univariable analysis (HR: 1.77, 95% CI: 1.31–2.38; p < 0.001) and remained associated with worse OS after adjustment for baseline clinicopathological factors, first-line treatment category, and diagnosis period (adjusted HR: 1.77, 95% CI: 1.24–2.53; p = 0.002). The PFS difference between the CALLY groups was not statistically significant (HR: 1.15, 95% CI: 0.87–1.51; p = 0.326). Conclusions: Low baseline CALLY was independently associated with shorter OS in this retrospective cohort. These findings support CALLY as a practical candidate prognostic biomarker, while external validation and time-to-event-based cut-off assessment are needed before clinical implementation.